Johnson & Johnson discovered that only a small percentage (10-15%) of their AI use cases are responsible for the majority (80%) of the value generated. After a three-year period of encourag…
Johnson & Johnson discovered that only a small percentage (10-15%) of their AI use cases are responsible for the majority (80%) of the value generated. After a three-year period of encouraging AI experimentation among employees, the company analyzed nearly 900 use cases to determine which projects were most successful.
They are now focusing resources on high-value applications like a generative AI sales coach and an internal employee chatbot. Johnson & Johnson is also developing AI tools for drug discovery and supply chain risk mitigation. This shift comes after realizing the need to prioritize and scale successful AI implementations for maximum impact.
A PYMNTS Intelligence report confirms that many healthcare firms are already seeing positive ROI from GenAI investments, particularly in product innovation and customer service.